ARN19689 

ARN19689 is a potent, selective, orally active and non-covalent inhibitor of N‑Acylethanolamine-Hydrolyzing Acid Amidase (NAAA), with an IC₅₀ of 42 nM. ARN19689 is a promising pharmacological tool to be further investigated in the field of inflammatory conditions^[1].

IC50: 42 nM (N‑Acylethanolamine-Hydrolyzing Acid Amidase)^[1]

ARN19689 (30 μM) inhibits the activity of human FAAH and human acid ceramidase by 25 and 34%, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ARN19689 exhibits high plasma concentrations following i.v. (3 mg/kg) and p.o. (10 mg/kg) administration, low volume of distribution and clearance, and good oral bioavailability in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

421.51

C₁₉H₂₇N₅O₄S

2320521-34-2

O=S(N1[C@@H]2C[C@H](C[C@H]1CC2)OC3=NC=C(COCC)N=C3)(C4=C(C)NN=C4C)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Di Fruscia P, et al. Discovery and SAR Evolution of Pyrazole Azabicyclo[3.2.1]octane Sulfonamides as a Novel Class of Non-Covalent N-Acylethanolamine-Hydrolyzing Acid Amidase (NAAA) Inhibitors for Oral Administration. J Med Chem. 2021 Sep 23;64(18):13327-  [Content Brief]